中国全科医学
中國全科醫學
중국전과의학
CHINESE GENERAL PRACTICE
2010年
5期
471-473
,共3页
郑三晖%曾哲%黄明通%刘少飞
鄭三暉%曾哲%黃明通%劉少飛
정삼휘%증철%황명통%류소비
高血压%复方缬沙坦%心脏扩大%左室舒张功能
高血壓%複方纈沙坦%心髒擴大%左室舒張功能
고혈압%복방힐사탄%심장확대%좌실서장공능
Hypertension%Valsartan/HCTZ%Cardiomegaly%Left ventricular diastolic function
目的 观察复方缬沙坦对轻-中度原发性高血压左室肥厚及舒张功能的影响.方法 收集轻-中度原发性高血压伴左室肥厚患者102例,经洗脱2周后随机分为两组,观察组(n=62)患者口服复方缬沙坦(缬沙坦80 mg+氢氯噻嗪12.5 mg),对照组(n=40)患者口服缬沙坦(80 mg/d),均治疗30周.比较两组患者治疗前后的血压、心率、左室重量指数(LVMI)、左室等容舒张时间(IVRT)、舒张早期峰值速度(E)/舒张晚期峰值速度(A)比值及E峰减速时间(DT).结果 两组患者治疗30周后血压、LVMI、IVRT、DT及E/A比值均较治疗前显著改善(P<0.05).观察组患者治疗后收缩压、舒张压降低幅度[(37±10)mm Hg和(22±6)mm Hg]均显著大于对照组[(26±10)mm Hg和(11±5)mm Hg],差异有统计学意义(P<0.05);且LVMI、IVRT、DT减少幅度[(18±7)g/m~2、(22±9)ms和(90±18)ms],均显著大于对照组[(14±6)g/m~2、(18±7)ms和(81±20)ms],E/A比值升幅(0.68±0.3)亦显著大于对照组(0.48±0.2),差异均有统计学意义(P<0.05).结论 复方缬沙坦及缬沙坦在有效降低轻-中度原发性高血压患者血压水平的同时,能明显改善左室肥厚及舒张功能,前者效果更显著.
目的 觀察複方纈沙坦對輕-中度原髮性高血壓左室肥厚及舒張功能的影響.方法 收集輕-中度原髮性高血壓伴左室肥厚患者102例,經洗脫2週後隨機分為兩組,觀察組(n=62)患者口服複方纈沙坦(纈沙坦80 mg+氫氯噻嗪12.5 mg),對照組(n=40)患者口服纈沙坦(80 mg/d),均治療30週.比較兩組患者治療前後的血壓、心率、左室重量指數(LVMI)、左室等容舒張時間(IVRT)、舒張早期峰值速度(E)/舒張晚期峰值速度(A)比值及E峰減速時間(DT).結果 兩組患者治療30週後血壓、LVMI、IVRT、DT及E/A比值均較治療前顯著改善(P<0.05).觀察組患者治療後收縮壓、舒張壓降低幅度[(37±10)mm Hg和(22±6)mm Hg]均顯著大于對照組[(26±10)mm Hg和(11±5)mm Hg],差異有統計學意義(P<0.05);且LVMI、IVRT、DT減少幅度[(18±7)g/m~2、(22±9)ms和(90±18)ms],均顯著大于對照組[(14±6)g/m~2、(18±7)ms和(81±20)ms],E/A比值升幅(0.68±0.3)亦顯著大于對照組(0.48±0.2),差異均有統計學意義(P<0.05).結論 複方纈沙坦及纈沙坦在有效降低輕-中度原髮性高血壓患者血壓水平的同時,能明顯改善左室肥厚及舒張功能,前者效果更顯著.
목적 관찰복방힐사탄대경-중도원발성고혈압좌실비후급서장공능적영향.방법 수집경-중도원발성고혈압반좌실비후환자102례,경세탈2주후수궤분위량조,관찰조(n=62)환자구복복방힐사탄(힐사탄80 mg+경록새진12.5 mg),대조조(n=40)환자구복힐사탄(80 mg/d),균치료30주.비교량조환자치료전후적혈압、심솔、좌실중량지수(LVMI)、좌실등용서장시간(IVRT)、서장조기봉치속도(E)/서장만기봉치속도(A)비치급E봉감속시간(DT).결과 량조환자치료30주후혈압、LVMI、IVRT、DT급E/A비치균교치료전현저개선(P<0.05).관찰조환자치료후수축압、서장압강저폭도[(37±10)mm Hg화(22±6)mm Hg]균현저대우대조조[(26±10)mm Hg화(11±5)mm Hg],차이유통계학의의(P<0.05);차LVMI、IVRT、DT감소폭도[(18±7)g/m~2、(22±9)ms화(90±18)ms],균현저대우대조조[(14±6)g/m~2、(18±7)ms화(81±20)ms],E/A비치승폭(0.68±0.3)역현저대우대조조(0.48±0.2),차이균유통계학의의(P<0.05).결론 복방힐사탄급힐사탄재유효강저경-중도원발성고혈압환자혈압수평적동시,능명현개선좌실비후급서장공능,전자효과경현저.
Objective To observe the effect of valsartan/hydrochlorothiazide(HCTZ) on left ventricular hypertrophy and diastolic function in patients with mild or moderate essential hypertension (EH).Methods One hundred two patients with mild or moderate EH and left ventricular hypertrophy were divided,after elution,into groups observation (n=62,receiving valsartan 80 mg+HCTZ 12.5 mg,30 weeks) and control (n=40,receiving valsartan 80 mg,30 weeks).Blood pressure (BP),heart rate (HR),left ventricular mass index (LVMI),left ventricular isovolumic relaxation time (IVRT),early diastolic peak velocity (E)/late diastolic peak velocity (A) ratio,E peak deceleration (DT) were determined.Results BP,LVMI,IVRT,DT and E/A ratio were significantly improved 30 weeks after treatement as compared with those before treatment (P<0.05).The reduction ranges of systolic and diastolic BP were significantly larger in observation group(37±10 mm Hg,22±6 mm Hg,respectively) than in control (26±10 mm Hg,11±5 mm Hg,respectively) (P<0.05); the reduction ranges of LVMI,IVRT,DT (18±7 g/m~2,22±9 ms,90±18 ms,respectively) were larger than in control (14±6 g/m~2,18±7 ms,81±20 ms,respectively); the extent of increase was larger in observation group (0.68±0.3) than in control (0.48±0.2) (P<0.05).Conclusion Both compound valsartan and valsartan treatments can reduce the BP levels of mild or moderate hypertensive patients and improve obviously left ventricular hypertrophy and diastolic function,but the former effects more remarkably.
